Trial Profile
Post-marketing Study Assessing the Long-Term Safety of Abatacept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2017
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 24 Apr 2017 Status changed from active, no longer recruiting to completed.
- 18 Nov 2014 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as per ClinicalTrails.gov record.
- 18 Nov 2014 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as per ClinicalTrails.gov record.